Masaru Niki, M.D., Ph.D.
Associate
Dr. Niki's research interests include the pathogenesis of chronic myelogenous leukemia (CML).
Honors, Awards, and Organizations
- American Society of Clinical Oncology, 2002-
- American Society of Hematology, 2002-
- Phi Beta Kappa, 1993-
Recent Publications
- Kashiwada, M., Cattoretti, G., Mckeag, L., Rouse, T., Showalter, B. M., Al-Alem, U., Niki, M., Pandolfi, P. P., Field, E. H. and Rothman P. B. Downstream of tyrosine kinases-1 and Src homology 2-containing inositol 5’-phosphatase are required for regulation of CD4+CD25+ T cell development. J. Immunol. 176: 3958-3965, 2006.
- Zhao, M., Janas, J. A., Niki, M., Pandolfi, P. P. and Van Aelst, L. Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathway to inhibit platelet-derived growth factor-induced mitogenesis. Mol. Cell. Biol. 26: 2479-2489, 2006.
- Chen, Z., Trotman, L., Shaffer, D., Lin, H-K., Dotan, Z. Niki, M., Koutcher, J., Scher, H., Ludwig, T., Gerald, W., Cordon-Cardo, C. and Pandolfi, P.P. Critical role of p53 dependent cellular senescence in suppression of Pten deficient tumourigenesis. Nature 436: 725-730, 2005.
|
Medical School:
Tohoku University School of Medicine, Sendai, Japan
Graduate School:
Graduate School of Medicine, Tohoku University, Sendai, Japan
Residency:
Tohoku University Hospital, Japan
Hitachi General Hospital, Japan |
